8-K: Bausch + Lomb Reports Strong Q3 Revenue, Raises EBITDA Outlook

Bausch + Lomb Corporation announced third-quarter 2025 financial results, reporting broad-based revenue growth and an updated, higher full-year Adjusted EBITDA guidance.

Summary

• Total reported revenue for Q3 2025 was $1.281 billion, an increase of 7% as reported and 6% on a constant currency basis compared to Q3 2024.
• GAAP Net Loss attributable to Bausch + Lomb Corporation for Q3 2025 was $28 million, compared to net income of $4 million in Q3 2024.
• Adjusted EBITDA (non-GAAP) was $243 million for Q3 2025, an increase of $31 million from $212 million in Q3 2024.
• Adjusted EBITDA excluding Acquired IPR&D (non-GAAP) was $243 million for Q3 2025, up $16 million from $227 million in Q3 2024.
• Operating income for Q3 2025 was $95 million, a significant increase from $43 million in Q3 2024.
• Full-year 2025 Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP) guidance was updated to a range of $870 million $910 million, from the previous range of $860 million $910 million.
• Cash, cash equivalents and restricted cash stood at $332 million as of September 30, 2025.

Sentiment

Score: 7

Explanation: The company demonstrated strong operational performance with significant revenue growth across all segments and increased adjusted profitability metrics. The upward revision of full-year Adjusted EBITDA guidance, attributed to strong business performance, indicates positive momentum. While a GAAP net loss was reported, the underlying business trends and R&D pipeline advancements suggest a positive outlook.

Positives

• Delivered broad-based revenue growth across all segments, with total revenue increasing 7% as reported and 6% on a constant currency basis.
• Expanded leadership in dry eye with strong growth in MIEBO product sales.
• Regained momentum in premium IOLs (intraocular lenses) with growth in enVista and LUX platforms.
• Advanced the R&D pipeline, including a next-gen LUMIFY Phase 3 study meeting all primary and secondary endpoints.
• Initiated enrollment for several new clinical studies, including bioactive lens, next-gen lifitegrast, ocular surface pain, and glaucoma programs.
• Operating income increased by $52 million, driven by higher sales and operating expense efficiencies.
• Adjusted EBITDA (non-GAAP) increased by $31 million, reflecting improved operational performance.
• Updated full-year 2025 Adjusted EBITDA guidance, narrowing the range and increasing the lower end, attributed to strong business performance.

Negatives

• Reported a GAAP Net Loss attributable to Bausch + Lomb Corporation of $28 million for Q3 2025, an unfavorable change from net income of $4 million in Q3 2024.
• GAAP Earnings Per Share (EPS) was a loss of ($0.08) for Q3 2025, compared to an income of $0.01 in Q3 2024.
• Cash flow from operations decreased by $17 million to $137 million in Q3 2025, primarily due to business transformation payments.
• An increase in income tax provision contributed to the GAAP net loss.

Risks

• Uncertainties regarding the proposed plan to separate Bausch + Lomb into an independent, publicly traded company from Bausch Health Companies Inc. (BHC), including expected benefits, costs, timing, and conditions for completion.
• Potential impact of any sales or dispositions of common shares by BHC, including in connection with foreclosure on shares pledged as collateral for BHC's debt.
• Risks that market or other conditions may no longer be favorable for completing the separation transaction, or that necessary approvals are not obtained.
• Business disruption during the pendency of or following the separation, diversion of management time, and retention of existing management team members.
• Potential dis-synergy costs resulting from the separation and impact on relationships with customers, suppliers, employees, and other business counterparties.
• Risks related to acquisitions and other business development transactions, including failure to close, not realizing expected benefits, and increased debt levels.
• Risks associated with the voluntary recall of certain enVista IOL products, including ability to resupply inventory and success of enhanced protocols.
• Expected impact of tariffs imposed by the U.S. and counter-tariffs, disruptions to global supply chains, and ability to manage these measures.
• Adverse economic conditions and other macroeconomic factors, such as heightened inflation, interest rates, fluctuations in exchange rates, and potential recession, which could impact revenue, expenses, and margins.

Future Outlook

Management updated its full-year 2025 Adjusted EBITDA Excluding Acquired IPR&D guidance to $870 million $910 million, citing strong business performance. The company maintained its full-year revenue guidance of $5.050 billion $5.150 billion, expecting approximately 5-7% constant currency growth. An investor day is planned in a few weeks to showcase the company's loaded and differentiated pipeline of clinical-stage programs.

Management Comments

• "We’re delivering on the vision we laid out in 2023, with a base business engine that continues to hum and steady introduction of innovative products across categories."
• "Our loaded and differentiated pipeline featuring clinical-stage programs will be on full display in just a few weeks at investor day."

Industry Context

The company's performance reflects positive trends in the eye health industry, particularly in the dry eye segment with strong growth from MIEBO, and a resurgence in demand for premium intraocular lenses (IOLs). Continued investment in a diverse R&D pipeline, including advancements in next-gen LUMIFY and new clinical studies for bioactive lenses, lifitegrast, ocular surface pain, and glaucoma, positions the company to capitalize on evolving patient needs and competitive landscapes in the global eye care market.

Stakeholder Impact

• Shareholders: Mixed Q3 results with a GAAP net loss but strong operational growth and an improved full-year Adjusted EBITDA outlook, suggesting potential for future value.
• Customers: Benefit from continued innovation and product advancements in dry eye, premium IOLs, and a robust R&D pipeline addressing various eye health needs.

Next Steps

• Host an investor day in a few weeks to showcase the company's clinical-stage R&D pipeline.

Key Dates

Recommendation

The company exhibits strong underlying operational performance with robust revenue growth across all key segments and significant increases in operating income and Adjusted EBITDA. The positive advancements in the R&D pipeline, including successful Phase 3 results for next-gen LUMIFY, signal future growth potential. Management's decision to raise the lower end of the full-year Adjusted EBITDA guidance, explicitly citing strong business performance, reinforces confidence in the company's trajectory. While a GAAP net loss was reported, the emphasis on adjusted metrics and the overall positive operational momentum suggest a favorable investment opportunity.

Keywords

Eye Health, Vision Care, Pharmaceuticals, Surgical, Contact Lenses, IOLs, Dry Eye, LUMIFY, MIEBO, Financial Results, Earnings, SEC Filing, BLCO